12/30
08:42 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/29
04:27 pm
uncy
Unicycive resubmits NDA for hyperphosphatemia asset [Seeking Alpha]
Medium
Report
Unicycive resubmits NDA for hyperphosphatemia asset [Seeking Alpha]
12/29
07:47 am
uncy
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth [Yahoo! Finance]
Medium
Report
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth [Yahoo! Finance]
12/29
07:21 am
uncy
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) [Yahoo! Finance]
12/29
07:05 am
uncy
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Medium
Report
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
12/10
11:42 am
uncy
2025 Forbes Healthcare Summit | How To Make Medicine Personal [Forbes]
Low
Report
2025 Forbes Healthcare Summit | How To Make Medicine Personal [Forbes]
11/25
01:58 pm
uncy
Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
08:01 am
uncy
Unicycive Therapeutics to Participate in Upcoming Investor Events in December [Yahoo! Finance]
Low
Report
Unicycive Therapeutics to Participate in Upcoming Investor Events in December [Yahoo! Finance]
11/25
07:05 am
uncy
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Medium
Report
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
11/18
06:27 am
uncy
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well [Yahoo! Finance]
Low
Report
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well [Yahoo! Finance]
11/12
08:19 am
uncy
Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07 [Seeking Alpha]
Medium
Report
Unicycive Therapeutics GAAP EPS of -$0.46 beats by $0.07 [Seeking Alpha]
11/12
07:35 am
uncy
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
07:05 am
uncy
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
11/3
07:05 am
uncy
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
11/2
01:15 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by analysts at
Wall St
Medium
Report
Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by analysts at
Wall St
11/2
01:15 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by analysts at
Wall St
Medium
Report
Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by analysts at
Wall St
10/31
12:05 pm
uncy
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/30
12:32 pm
uncy
Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Unicycive Therapeutics (NASDAQ:UNCY) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/30
07:05 am
uncy
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
Neutral
Report
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
10/29
08:02 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Unicycive Therapeutics (NASDAQ:UNCY) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/28
07:05 am
uncy
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
Medium
Report
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
10/25
01:32 am
uncy
Unicycive Therapeutics (NASDAQ:UNCY) was downgraded by analysts at
Wall
Low
Report
Unicycive Therapeutics (NASDAQ:UNCY) was downgraded by analysts at
Wall